Cardiorenalmetabolic

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

A new joint guideline from the American Heart Association and the American College of Cardiology emphasizes early treatment, close perinatal blood pressure monitoring, and incorporating the PREVENT risk calculator to personalize care.

Metabolic syndrome severity is a meaningful marker of chronic kidney disease risk even when patients do not have other major risk factors.

A review of 59 studies finds inconsistent knowledge, attitudes, and practices among health care professionals in detecting diabetic retinopathy.

Evolocumab is now indicated for adults who don’t have a prior cardiovascular disease diagnosis.

As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.

Women who experienced stalking or intimate partner violence were 40% more likely to self-diagnose an adverse cardiovascular event compared with women who did not.

The use of retinal images can help investigators noninvasively identify chronic kidney disease and assess patient prognosis.

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and cholesterol, but also a $80 monthly rise in health care spending outside of drug costs.

A new American Heart Association initiative is working to increase screening for lipoprotein(a) (Lp[a]) at community health centers nationwide to help address undetected cardiovascular risk.

A meta-analysis reveals a significant link between chronic kidney disease (CKD) and gastroesophageal reflux disease (GERD), highlighting the need for increased screening and awareness.

Nurses enhance chronic kidney disease (CKD) care by implementing a palliative CKD care framework, addressing barriers, and promoting patient-centered supportive strategies globally.

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year after an elevated blood pressure reading.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events, based on FINEARTS-HF trial results.

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Iptacopan targets one of the major proteins involved in the enzymes of the alternative pathway of complement, explains Carla Nester, MD, of Stead Family Children's Hospital.

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these gains easier to maintain, explained Hamlet Gasoyan, PhD.

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Merrill H. Stewart, MD, Ochsner Health, outlines the financial, logistical, and reimbursement barriers slowing the adoption of cardiac stress testing, but growing recognition of its long-term value could drive wider use.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP-1) receptor agonists, reducing their effectiveness for weight loss, explains Hamlet Gasoyan, PhD, Cleveland Clinic.

Merrill H. Stewart, MD, Ochsner Health, explains misconceptions about stents and bypass surgery and highlights when cardiac positron emission tomography (PET) stress testing is most appropriate.

According to Merrill H. Stewart, MD, Ochsner Health, the test can more accurately identify high-risk patients while helping others avoid unnecessary invasive procedures.

A pharmaceutical-grade cannabidiol (CBD) product was shown to be safe in high-risk patients hospitalized with COVID-19, with no increased rate of cardiac side effects compared with placebo.

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

Offspring born to mothers with prepregnancy obesity, gestational diabetes, or hypertensive disorders of pregnancy had higher systolic and diastolic blood pressure levels than those born to mothers without these risk factors.

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.